Sunday, April 2, 2023 4/2/2023

Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer

Award Number: R37CA227101
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY The androgen receptor has been a target of prostate cancer for over 70 years with the evolution of pharmacotherapy ranging from chemical castration, small molecular inhibition of anabolic enzymes, to blockade of dihydrotestosterone. Despite the variety of these approaches none of these approaches are acceptable for long term treatment across the prostate cancer continuum. Our long term goal is to identify dietary and semi- synthetic xanthones that may inspire a new class of compounds as Selective Androgen Receptor Degraders (SARDs) for prevention and/or treatment of prostate cancer including castration resistant prostate cancer. New approaches are needed because FDA approved drugs for prostate cancer including enzalutamide and abiraterone can develop resistance in as little as 3-6 months of therapy initiation. The mangosteen fruit is a rich source of xanthones including a-mangostin, gartanin and others with more than 80 unique xanthones identified. a-Mangostin and gartanin were chosen from 9 xanthones for our preliminary studies to evaluate xanthones as SARDs. Using an approach incorporating natural products chemistry isolation we will create 4 different mangosteen extracts with different xanthones. We will fully characterize these extracts chemically and mechanistically for AR and AR splice variant (i.e. including AR-V7 a marker of resistance) degradation in vitro and in vivo as well as pharmacokinetic properties including dosing parameters, microsome analysis and p450 interactions. Our central hypothesis is that mangosteen derived xanthones are SARDs that bind to the AR preventing the nuclear translocation and dimerization of AR. Additionally, selected xanthones inhibit kinases that have been shown to post-translationally modify AR. This leads to a decrease in proliferation inducing endoplasmic reticulum stress. The chaperone protein BiP, a marker of endoplasmic reticulum stress, is activated and binds AR directly leading to proteolytic degradation of wild type AR and AR-V7 (a splice variant of AR responsible for anti-androgen resistance). Our objective in this proposal is to identify xanthones with the greatest potential for broad application across the prostate carcinogenesis continuum spanning diagnosis to castration resistance prostate cancer similar to anti-estrogens used to treat prostate cancer. Specific Aim 1. Elucidate how a-mangostin and gartanin disrupt the functionality and translocation of the androgen receptor to the nucleus leading to the proteasomal degradation of androgen receptor. Specific Aim 2. Identify the most active mangosteen extract for AR degradation disruption using a xenograft mouse model while characterizing the pharmacokinetic parameters of xanthones. Specific Aim 3. Determine if oral administration of a well-defined mangosteen fruit extract will inhibit the development of LG-PIN to HG-PIN to prostate cancer in TRAMP mice through disruption of AR.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $346,361 )
2023	2023	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	002	5	3/14/2023	NON-COMPETING CONTINUATION	$28,274
2023	2023	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	001	5	1/19/2023	NON-COMPETING CONTINUATION	$0
2023	2023	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	000	5	12/23/2022	NON-COMPETING CONTINUATION	$318,087


Issue Date FY: 2022 ( Subtotal = $353,430 )
2022	2022	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	000	4	1/31/2022	NON-COMPETING CONTINUATION	$318,087
2022	2022	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	001	4	6/17/2022	NON-COMPETING CONTINUATION	$35,343


Issue Date FY: 2021 ( Subtotal = $353,431 )
2021	2021	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	001	3	1/25/2021	NON-COMPETING CONTINUATION	$17,673
2021	2021	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	000	3	12/22/2020	NON-COMPETING CONTINUATION	$335,758


Issue Date FY: 2020 ( Subtotal = $352,420 )
2020	2020	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	000	2	12/20/2019	NON-COMPETING CONTINUATION	$317,178
2020	2020	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	001	2	1/13/2020	NON-COMPETING CONTINUATION	$35,242


Issue Date FY: 2019 ( Subtotal = $352,420 )
2019	2019	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Cancer Cause and Prevention Research	000	1	12/13/2018	NEW	$352,420


Grand Total All Awards = $1,758,062

Sum of Action Amount is $1,758,062;

Grand Total = $1,758,062

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer

Award Number: R37CA227101

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer